Infant Adrenal Insufficiency Following Postnatal Lopinavir/r

Reports of this potential toxicity should not preclude the use of postnatal lopinavir/ritonavir, but they do indicate the need for some precautions.

Treatment of HIV-infected pregnant women, coupled with postnatal antiretrovirals for their infants, has led to a dramatic decrease in mother-to-child transmission of HIV. Lopinavir/ritonavir is the only “preferred” protease inhibitor in pregnancy, according to U.S. perinatal guidelines, and is frequently used in newborns as well, even though it is not licensed for use in infants younger than 14 days. Recent reports have described possible systemic and cardiac lopinavir/r toxicity in preterm infants, prompting an FDA warning, but no population-based data exist.

In this retrospective, cross-sectional analysis of HIV-exposed infants in the French Perinatal Cohort, researchers compared clinical symptoms, 17-hydroxyprogesterone (17OHP) levels, an…

Reviewing Authors

Sean Cook, MD

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Infant Adrenal Insufficiency Following Postnatal Lopinavir/r

Topics

Reviewing Authors